Patrick A Baeuerle

Summary

Publications

  1. ncbi BiTE: Teaching antibodies to engage T-cells for cancer therapy
    Patrick A Baeuerle
    Micromet Inc, 6707 Democracy Boulevard, Suite 505, Bethesda, MD 20817, USA
    Curr Opin Mol Ther 11:22-30. 2009
  2. pmc Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells
    Ines Herrmann
    Micromet AG, Munich, Germany
    PLoS ONE 5:e13474. 2010
  3. pmc EpCAM (CD326) finding its role in cancer
    P A Baeuerle
    Micromet, Inc, 2110 Rutherford Road, Carlsbad, CA, 92008, USA
    Br J Cancer 96:417-23. 2007
  4. doi Bispecific T-cell engaging antibodies for cancer therapy
    Patrick A Baeuerle
    Micromet Inc, Bethesda, Maryland, USA
    Cancer Res 69:4941-4. 2009
  5. pmc Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
    Markus Munz
    Micromet AG, Staffelseestr, 2, 81477 Munich, Germany
    Cancer Cell Int 10:44. 2010
  6. ncbi Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
    Klaus Brischwein
    Micromet AG, Munich, Germany
    J Immunother 30:798-807. 2007
  7. ncbi Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
    Bernd Schlereth
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Cancer Immunol Immunother 55:785-96. 2006
  8. ncbi MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
    Klaus Brischwein
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Mol Immunol 43:1129-43. 2006
  9. doi Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
    Maria Amann
    Micromet AG, Munich, Germany
    Cancer Immunol Immunother 58:95-109. 2009
  10. doi Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
    Maria Amann
    Micromet AG, Munich, Germany
    J Immunother 32:452-64. 2009

Collaborators

Detail Information

Publications58

  1. ncbi BiTE: Teaching antibodies to engage T-cells for cancer therapy
    Patrick A Baeuerle
    Micromet Inc, 6707 Democracy Boulevard, Suite 505, Bethesda, MD 20817, USA
    Curr Opin Mol Ther 11:22-30. 2009
    ..The potential of global T-cell engagement for human cancer therapy by T-cell-engaging antibodies has yet to be fully investigated...
  2. pmc Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells
    Ines Herrmann
    Micromet AG, Munich, Germany
    PLoS ONE 5:e13474. 2010
    ..T cells engaged by MT110 may provide a potent therapeutic means to eradicate TICs and bulk tumor cells derived thereof...
  3. pmc EpCAM (CD326) finding its role in cancer
    P A Baeuerle
    Micromet, Inc, 2110 Rutherford Road, Carlsbad, CA, 92008, USA
    Br J Cancer 96:417-23. 2007
    ..Future research on EpCAM may benefit from a unified nomenclature and more frequent exchange among those who have been working on this cancer target during the past 30 years and will do so in the future...
  4. doi Bispecific T-cell engaging antibodies for cancer therapy
    Patrick A Baeuerle
    Micromet Inc, Bethesda, Maryland, USA
    Cancer Res 69:4941-4. 2009
    ..Recent results from clinical studies with a CD19/CD3-bispecific BiTE antibody suggest that this therapeutic paradigm is finally showing promise for treatment of both bulky and minimal residual disease...
  5. pmc Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
    Markus Munz
    Micromet AG, Staffelseestr, 2, 81477 Munich, Germany
    Cancer Cell Int 10:44. 2010
    ..Here we compared all anti-EpCAM antibodies in an attempt to explain differences in clinical activity and safety...
  6. ncbi Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
    Klaus Brischwein
    Micromet AG, Munich, Germany
    J Immunother 30:798-807. 2007
    ..BiTE molecules therefore qualify for a highly controlled polyclonal T-cell therapy of cancer...
  7. ncbi Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
    Bernd Schlereth
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Cancer Immunol Immunother 55:785-96. 2006
    ..Our study shows that BiTEs also have a high antitumor activity in immunocompetent mice and that there is no obvious need for costimulation of T cells by secondary agents...
  8. ncbi MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
    Klaus Brischwein
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Mol Immunol 43:1129-43. 2006
    ..MT110 appears as an attractive bispecific antibody candidate for treatment of human Ep-CAM-overexpressing carcinomas...
  9. doi Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
    Maria Amann
    Micromet AG, Munich, Germany
    Cancer Immunol Immunother 58:95-109. 2009
    ..Because humans have extremely low numbers of EpCAM(+) cells in blood, this toxicity of an EpCAM-specific BiTE may be specific for mice...
  10. doi Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
    Maria Amann
    Micromet AG, Munich, Germany
    J Immunother 32:452-64. 2009
    ..Finally, we show that muS110 and MT110 recognize orthologous epitopes on mouse and human EpCAM proteins, suggesting that the target-related safety profile of muS110 in mice may be predictive for MT110 in humans...
  11. ncbi Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model
    Petra Lutterbuese
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Cancer Immunol Immunother 56:459-68. 2007
    ..Moreover, our data suggest to routinely compare in mouse models human IgG1 and murine IgG2a versions of antibodies to properly assess the contribution of ADCC to overall anti-tumor activity...
  12. ncbi The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
    Christian Brandl
    Micromet AG, Staffelseestr 2, 814777, Munich, Germany
    Cancer Immunol Immunother 56:1551-63. 2007
    ..Glucocorticoids thus qualify as a potential co-medication for therapeutic BiTE molecules and other cytotoxic T cell therapies for treatment of cancer...
  13. ncbi Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct
    Scott A Hammond
    MedImmune, Inc, Gaithersburg, Maryland 20878, USA
    Cancer Res 67:3927-35. 2007
    ....
  14. ncbi T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
    Bernd Schlereth
    Micromet AG, Staffelseestr 2, 81477, Munich, Germany
    Cancer Immunol Immunother 55:503-14. 2006
    ..A clinical trial testing prolonged administration of bscCD19xCD3 (MT103) for improving efficacy is currently ongoing...
  15. doi Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
    Cornelia Haas
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Immunobiology 214:441-53. 2009
    ..Our study shows that MT110 can efficiently gear up the potential of CD8(+) and CD4(+) T cells for serial lysis, and mediate kill of cancer cells predominantly through poreforming and pro-apoptotic components of cytotoxic T cell granules...
  16. ncbi Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
    Patrick Hoffmann
    Micromet AG, Munich, Germany
    Int J Cancer 115:98-104. 2005
    ..To our knowledge, this is the first study showing that a bispecific antibody can sustain multiple rounds of target cell lysis by T cells...
  17. doi Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
    Sandrine D'Argouges
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Leuk Res 33:465-73. 2009
    ..Combination of rituximab with blinatumomab was found to greatly enhance the activity of rituximab, in particular at low effector-to-target cell ratios and at low antibody concentration...
  18. ncbi Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells
    Juergen M Schanzer
    Micromet AG, Staffelseestrasse 2, 81477 Munich, Germany
    J Immunother 29:477-88. 2006
    ....
  19. ncbi CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
    Michael Mølhøj
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Mol Immunol 44:1935-43. 2007
    ..The extraordinary potency of the BiTE class and its representative MT103 may translate into improved anti-tumor activity, lower dosing and lower costs of production compared to other bispecific antibody formats...
  20. doi Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
    Ralf Lutterbuese
    Micromet AG, Staffelseestrasse 2, Munich, Germany
    J Immunother 32:341-52. 2009
    ..Together, our results reveal a unique opportunity for targeting cytotoxic T cells toward CEA-expressing tumors without being competitively inhibited by sCEA and establish CEA/CD3-bscAb as a promising and potent therapeutic approach...
  21. doi Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3
    Maria Amann
    Micromet AG, Munich, Germany
    Cancer Res 68:143-51. 2008
    ..MuS110 was found to have similar in vitro characteristics and in vivo antitumor activity as MT110, a human EpCAM/human CD3-bispecific BiTE antibody that currently is in formal preclinical development...
  22. doi Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
    Claudia Bluemel
    Micromet AG, Staffelseestr 2, 81477, Munich, Germany
    Cancer Immunol Immunother 59:1197-209. 2010
    ..In case of the MCSP antigen, this provides the basis for selection of a maximally potent BiTE antibody candidate for development of a novel melanoma therapy...
  23. ncbi A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells
    Juergen M Schanzer
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Cancer Immun 6:4. 2006
    ....
  24. ncbi Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
    Bernd Schlereth
    Micromet AG, Munich, Germany
    Cancer Res 65:2882-9. 2005
    ..Our data show that the class of single-chain bispecific antibodies has very high antitumor efficacy in vivo and can use previously unstimulated T cells at low effector-to-target ratios...
  25. ncbi A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes
    Marcel Zocher
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Mol Immunol 41:511-8. 2004
    ..Fusions between autoantigens and an anti-CD3 single-chain antibody may be suitable to develop very specific therapeutic approaches for the selective depletion of autoreactive B cells in autoimmune diseases...
  26. pmc Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells
    Jutta Steigerwald
    Micromet AG, Munich, Germany
    MAbs 1:115-27. 2009
    ..Based on these results, anti-human NKG2D mAb E4 provides an ideal candidate for development of a novel therapeutic agent antagonizing a key receptor of NK and cytotoxic T cells with implications in autoimmune diseases...
  27. ncbi T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct
    Torsten Dreier
    Micromet AG, Munich, Germany
    J Immunol 170:4397-402. 2003
    ..These properties make bscCD19xCD3 superior to previously investigated CD19 bispecific Ab-based therapies...
  28. ncbi Targeting of humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple epitopes on denatured collagens
    Bruce Freimark
    Micromet, Inc, MD, USA
    Mol Immunol 44:3741-50. 2007
    ..Our data suggest that D93 inhibits angiogenesis and tumor growth by blockade of cryptic bioactive signals on proteolyzed collagens with importance for growth of tumors and new blood vessels...
  29. pmc Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110
    Silke Petsch
    Micromet Inc, Bethesda, MD, USA
    MAbs 3:31-7. 2011
    ..We conclude that soluble EpEX in sera of cancer patients is unlikely to pose an issue for the efficacy or safety of MT110, and perhaps other antibodies binding to N-terminal epitopes of EpCAM...
  30. doi Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens
    Matthias Friedrich
    Baeuerle, Amgen Research GmbH, Munich, Germany
    Mol Cancer Ther 11:2664-73. 2012
    ..On the basis of these preclinical results, AMG 212/BAY2010112 appears as a promising new BiTE antibody for the treatment of patients with PSMA-expressing PCa...
  31. doi Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
    Dirk Nagorsen
    Micromet AG, Germany
    Leuk Lymphoma 50:886-91. 2009
    ..Here, we review the current progress in development of blinatumomab for treatment of patients with CD19-expressing hematological malignancies...
  32. ncbi High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G
    Susanne Preithner
    Micromet AG, Staffelseestrasse 2, 81477 Munich, Germany
    Mol Immunol 43:1183-93. 2006
    ..Competition of serum IgG for binding of therapeutic IgG1 to NK cell may be one important reason why high antibody doses are required in the clinic for treatment of cancer by an ADCC-based mechanism...
  33. pmc T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
    Ralf Lutterbuese
    Micromet, 81477 Munich, Germany
    Proc Natl Acad Sci U S A 107:12605-10. 2010
    ..EGFR-specific BiTE antibodies may have potential to treat CRC that does not respond to conventional antibodies...
  34. ncbi Highly efficient antigen targeting to M-DC8+ dendritic cells via FcgammaRIII/CD16-specific antibody conjugates
    Ines Mende
    Micromet AG, Staffelseestrasse 2, 81477 Munich, Germany
    Int Immunol 17:539-47. 2005
    ..Our data demonstrate that specific antigen targeting via CD16 on M-DC8(+) DC is a promising vaccination approach for the efficient induction of specific CD4(+) T cell responses ex vivo, and perhaps in vivo...
  35. ncbi A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex
    Jorg Volkland
    Micromet, Inc, 2110 Rutherford Road, Carlsbad, CA 92008, USA
    Mol Immunol 44:1743-53. 2007
    ..MT204 has potential as a novel immunosuppressive and anti-proliferative therapy with an apparently broader spectrum of activities than anti-CD25 antibodies...
  36. ncbi Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
    Torsten Dreier
    Micromet AG, Am Klopferspitz 19, 82152 Martinsried, Germany
    Int J Cancer 100:690-7. 2002
    ..In conclusion, bscCD19xCD3 could redirect unstimulated cytotoxic T cells against CD19-positive cells in an unexpectedly potent, rapid and specific fashion...
  37. ncbi Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
    Sonja Offner
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Mol Immunol 43:763-71. 2006
    ....
  38. ncbi BiTEs: bispecific antibody constructs with unique anti-tumor activity
    Evelyn Wolf
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Drug Discov Today 10:1237-44. 2005
    ....
  39. ncbi A revival of bispecific antibodies
    Peter Kufer
    Micromet AG, Staffelseestrasse 2, 81477 Munich, Germany
    Trends Biotechnol 22:238-44. 2004
  40. doi The emerging role of EpCAM in cancer and stem cell signaling
    Markus Munz
    Micromet AG, Munich, Germany
    Cancer Res 69:5627-9. 2009
    ..EpCAM has oncogenic potential and is activated by release of its intracellular domain, which can signal into the cell nucleus by engagement of elements of the wnt pathway...
  41. ncbi A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF
    Eva Maria Krinner
    Micromet AG, Staffelseestr 2, D 81477 Munich, Germany
    Mol Immunol 44:916-25. 2007
    ..Based on its favorable properties, MT203 has been selected for development as a novel anti-inflammatory human monoclonal antibody with therapeutic potential in a multitude of human autoimmune and inflammatory diseases...
  42. ncbi Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy
    Sonja Offner
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Cancer Immunol Immunother 54:431-45. 2005
    ....
  43. doi CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
    Christina Krupka
    Department of Internal Medicine III, Klinikum der Universitat Munchen, Munich, Germany
    Blood 123:356-65. 2014
    ..Targeting CD33 ex vivo using AMG 330 in primary AML samples led to T cell recruitment and expansion and remarkable antibody-mediated cytotoxicity, suggesting efficient therapeutic potential in vivo. ..
  44. doi Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
    Matthias Klinger
    Amgen Research Munich GmbH, Munich, Germany
    Blood 119:6226-33. 2012
    ..The trial is registered with www.clinicaltrials.gov identifier NCT00560794...
  45. ncbi In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
    Stefanie Naundorf
    Micromet AG, Martinsried, Germany
    Int J Cancer 100:101-10. 2002
    ..The fully human nature and the improved ADCC of MT201 with human effector cells will make MT201 a promising candidate for the clinical development of a novel pan-carcinoma antibody that is superior to edrecolomab...
  46. ncbi Bispecific antibodies for polyclonal T-cell engagement
    Patrick A Baeuerle
    Micromet AG, Staffelseestr 2, 81477 Munich, Germany
    Curr Opin Mol Ther 5:413-9. 2003
    ..Studying the mechanism of action of newly developed single-chain bispecific antibodies could provide insight into the shortcomings of bispecific antibodies that have been studied previously...
  47. pmc Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells
    Hitoe Torisu-Itakura
    Department of Melanoma Research, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    J Immunother 34:597-605. 2011
    ..As MCSP is expressed on most human melanomas, immunotherapy with MCSP/CD3-bispecific antibodies merits clinical investigation...
  48. ncbi Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer
    Patrick A Baeuerle
    MGEN Research Munich GmbH, Munich, Germany
    Curr Pharm Biotechnol 13:1399-408. 2012
    ..Initial experience has recently been gained in the clinic with both technologies such that their fundamental differences can now be discussed on the basis of patient data...
  49. doi Blinatumomab: a historical perspective
    Dirk Nagorsen
    Amgen Research Munich GmbH, Staffelseestr 2, 81477 Munich, Germany
    Pharmacol Ther 136:334-42. 2012
    ..Here, we review how blinatumomab has so far been pre-clinically and clinically developed for the treatment of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia...
  50. ncbi Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo
    Marcel Zocher
    Micromet AG, 81477 Munich, Germany
    Int Immunol 15:789-96. 2003
    ..Such fusion proteins may provide a platform for the development of highly selective therapeutic approaches...
  51. ncbi Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach
    Flavia Pernasetti
    Cell Matrix, Inc, a subsidiary of Micromet Corporation, Carlsbad, CA 92008, USA
    Int J Oncol 29:1371-9. 2006
    ..Our data suggest that blockade of cryptic epitopes exposed on collagen IV during angiogenesis and tumor growth by a monoclonal antibody may provide a novel therapeutic modality for treatment of cancer and pathogenic neo-vascularization...
  52. ncbi A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha
    Annegret de Baey
    Micromet AG, Munich, Germany
    J Immunol 170:5089-94. 2003
    ..We infer that selective elimination of M-DC8(+) cells in inflammatory diseases has therapeutic potential...
  53. doi Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction
    Dietlind Zohlnhofer
    Medizinische Klinik und Deutsches Herzzentrum, Technischen Universitat Munchen, Munich, Germany
    Heart Vessels 23:230-42. 2008
    ..Impaired intercellular communication as suggested by decreased expression of desmoplakin may be an important feature of contractile dysfunction in HM...
  54. doi Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
    Dirk Nagorsen
    Micromet, Inc, 6707 Democracy Blvd, Bethesda, MD 20817, USA
    Exp Cell Res 317:1255-60. 2011
    ..High response rates and durable remissions are observed in first clinical trials, indicating that T cells can be potently redirected for efficient and lasting elimination of malignant cells...
  55. doi The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated
    Christine Plater-Zyberk
    Micromet Inc 6707 Democracy Blvd, Bethesda, MD 20817, USA
    Transpl Immunol 25:133-40. 2011
    ..The characteristics of MT204, displaying linear pharmacokinetics, half-life in the range expected for a human IgG, benign safety profile and signs of efficacy, warrant further development of this antibody for therapy...
  56. pmc Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
    N Prang
    Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
    Br J Cancer 92:342-9. 2005
    ....
  57. pmc Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
    P Went
    Institute of Pathology, University Hospital Basel, Schonbeinstrasse 40, 4003 Basel, Switzerland
    Br J Cancer 94:128-35. 2006
    ....
  58. ncbi Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
    A Löffler
    Department of Haematology, Oncology and Tumourimmunology, Robert Rossle Clinic, Charite, Humboldt University of Berlin, Berlin, Germany
    Leukemia 17:900-9. 2003
    ..Although anti-CD95 antibody CH-11 failed to induce apoptosis in lymphoma cells, we provide evidence that B-CLL cell depletion by bscCD3 x CD3 is mediated at least in part by apoptosis via the caspase pathway...